Dark horse enters the TPO race

Glaxo Wellcome and its Affymax Research Institute disclosed their entrance into the thrombopoiesis race last week, publishing in Science the ability of a synthetic peptide to mimic the specificity and potency of the natural hormone thrombopoietin (TPO).

TPO acts to stimulate the proliferation and maturation of megakaryocytes, the precursor cells that give rise to platelets, boosting platelet counts. This function is the basis for developing TPO as a therapeutic in a number of indications, including

Read the full 746 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE